RS63570B1 - Formulacija atazanavira i kobicistata za lečenje hiv-a - Google Patents

Formulacija atazanavira i kobicistata za lečenje hiv-a

Info

Publication number: RS63570B1
Authority: RS; Serbia
Prior art keywords: cobicistat; atazanavir; treatment formulation; hiv treatment; hiv
Prior art date: 2013-10-07

Application number

RS20220859A

Other languages

English (en)

Inventor

Otilia May Yue Koo

Faranak Nikfar

Jing Tao

Niranjan Kumar Kottala

Sailesh A Varia

Original Assignee

Bristol Myers Squibb Holdings Ireland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-07

Filing date

2014-10-06

Publication date

2022-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS63570(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-10-06 Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland

2022-10-31 Publication of RS63570B1 publication Critical patent/RS63570B1/sr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

RS20220859A 2013-10-07 2014-10-06 Formulacija atazanavira i kobicistata za lečenje hiv-a RS63570B1 (sr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361887574P	2013-10-07	2013-10-07
EP18179796.0A EP3421033B1 (en)	2013-10-07	2014-10-06	Hiv treatment formulation of atazanavir and cobicistat

Publications (1)

Publication Number	Publication Date
RS63570B1 true RS63570B1 (sr)	2022-10-31

Family

ID=51743576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20220859A RS63570B1 (sr)	2013-10-07	2014-10-06	Formulacija atazanavira i kobicistata za lečenje hiv-a
RS20181143A RS57882B1 (sr)	2013-10-07	2014-10-06	Formulacija atazanavira i kobicistata za lečenje hiv-a

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RS20181143A RS57882B1 (sr)	2013-10-07	2014-10-06	Formulacija atazanavira i kobicistata za lečenje hiv-a

Country Status (28)

Country	Link
US (2)	US20160038502A1 (sr)
EP (2)	EP3421033B1 (sr)
JP (2)	JP6574415B2 (sr)
KR (1)	KR102286386B1 (sr)
CN (1)	CN106029058A (sr)
AU (1)	AU2014332200B2 (sr)
BR (1)	BR112016007526A8 (sr)
CA (1)	CA2926650A1 (sr)
CL (1)	CL2016000787A1 (sr)
CY (1)	CY1121105T1 (sr)
DK (2)	DK3054926T3 (sr)
EA (1)	EA031172B1 (sr)
ES (2)	ES2927484T3 (sr)
HR (2)	HRP20221126T1 (sr)
HU (1)	HUE059757T2 (sr)
IL (1)	IL244881B (sr)
LT (2)	LT3421033T (sr)
MX (1)	MX368268B (sr)
MY (1)	MY178960A (sr)
PE (1)	PE20160596A1 (sr)
PL (2)	PL3054926T3 (sr)
PT (2)	PT3421033T (sr)
RS (2)	RS63570B1 (sr)
SA (1)	SA516370891B1 (sr)
SG (1)	SG11201602501VA (sr)
SI (2)	SI3054926T1 (sr)
SM (2)	SMT201800507T1 (sr)
WO (1)	WO2015054133A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2582877T3 (es) *	2010-04-09	2016-09-15	Bristol-Myers Squibb Holdings Ireland	Formulaciones de sulfato de atazanavir con un efecto de pH mejorado
AU2016343851B2 (en)	2015-10-30	2022-04-07	Cancer Prevention Pharmaceuticals, Inc.	Eflornithine and sulindac, fixed dose combination formulation
CA2937365C (en)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
ES2952878T3 (es) *	2016-08-08	2023-11-06	Hetero Labs Ltd	Una composición antirretroviral multiclase
US11045423B2 (en)	2016-08-08	2021-06-29	Hetero Labs Limited	Anti-retroviral compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5558071A (en) *	1994-03-07	1996-09-24	Combustion Electromagnetics, Inc.	Ignition system power converter and controller
US5849911A (en)	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
IL134830A0 (en) *	2000-03-01	2001-05-20	Chay 13 Medical Res Group N V	Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US6579851B2 (en) *	2000-03-14	2003-06-17	Amylin Pharmaceuticals, Inc.	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
EP2066699B1 (en) *	2006-09-25	2020-02-12	Archer-Daniels-Midland Company	Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same
KR101577698B1 (ko)	2007-02-23	2015-12-15	길리애드 사이언시즈, 인코포레이티드	치료제의 약동학적 특성의 조절제
KR20100033378A (ko) *	2007-06-22	2010-03-29	브리스톨-마이어스 스큅 컴퍼니	아타자나비르를 함유하는 정제 조성물
US20130084243A1 (en) *	2010-01-27	2013-04-04	Liliane Goetsch	Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009084036A2 (en) *	2007-12-20	2009-07-09	Matrix Laboratories Limited	Composition for treatment of viral infections
EP2889029A1 (en) *	2008-09-25	2015-07-01	Cephalon, Inc.	Liquid formulations of bendamustine
US20110028412A1 (en) *	2009-08-03	2011-02-03	Cappellos, Inc.	Herbal enhanced analgesic formulations
ES2582877T3 (es) *	2010-04-09	2016-09-15	Bristol-Myers Squibb Holdings Ireland	Formulaciones de sulfato de atazanavir con un efecto de pH mejorado

2014
- 2014-10-06 SM SM20180507T patent/SMT201800507T1/it unknown
- 2014-10-06 ES ES18179796T patent/ES2927484T3/es active Active
- 2014-10-06 SI SI201430857T patent/SI3054926T1/sl unknown
- 2014-10-06 PE PE2016000463A patent/PE20160596A1/es unknown
- 2014-10-06 KR KR1020167011723A patent/KR102286386B1/ko active Active
- 2014-10-06 CA CA2926650A patent/CA2926650A1/en not_active Abandoned
- 2014-10-06 BR BR112016007526A patent/BR112016007526A8/pt not_active Application Discontinuation
- 2014-10-06 EP EP18179796.0A patent/EP3421033B1/en active Active
- 2014-10-06 SG SG11201602501VA patent/SG11201602501VA/en unknown
- 2014-10-06 HU HUE18179796A patent/HUE059757T2/hu unknown
- 2014-10-06 PL PL14786421T patent/PL3054926T3/pl unknown
- 2014-10-06 LT LTEP18179796.0T patent/LT3421033T/lt unknown
- 2014-10-06 CN CN201480066184.XA patent/CN106029058A/zh active Pending
- 2014-10-06 WO PCT/US2014/059310 patent/WO2015054133A1/en active Application Filing
- 2014-10-06 DK DK14786421.9T patent/DK3054926T3/en active
- 2014-10-06 ES ES14786421.9T patent/ES2693580T3/es active Active
- 2014-10-06 EP EP14786421.9A patent/EP3054926B1/en active Active
- 2014-10-06 HR HRP20221126TT patent/HRP20221126T1/hr unknown
- 2014-10-06 MY MYPI2016701258A patent/MY178960A/en unknown
- 2014-10-06 SI SI201431985T patent/SI3421033T1/sl unknown
- 2014-10-06 PL PL18179796.0T patent/PL3421033T3/pl unknown
- 2014-10-06 RS RS20220859A patent/RS63570B1/sr unknown
- 2014-10-06 MX MX2016004078A patent/MX368268B/es active IP Right Grant
- 2014-10-06 EA EA201690594A patent/EA031172B1/ru not_active IP Right Cessation
- 2014-10-06 PT PT181797960T patent/PT3421033T/pt unknown
- 2014-10-06 SM SM20220373T patent/SMT202200373T1/it unknown
- 2014-10-06 RS RS20181143A patent/RS57882B1/sr unknown
- 2014-10-06 LT LTEP14786421.9T patent/LT3054926T/lt unknown
- 2014-10-06 AU AU2014332200A patent/AU2014332200B2/en active Active
- 2014-10-06 DK DK18179796.0T patent/DK3421033T3/da active
- 2014-10-06 JP JP2016520670A patent/JP6574415B2/ja active Active
- 2014-10-06 US US14/425,443 patent/US20160038502A1/en not_active Abandoned
- 2014-10-06 PT PT14786421T patent/PT3054926T/pt unknown
2016
- 2016-04-04 IL IL244881A patent/IL244881B/en unknown
- 2016-04-05 CL CL2016000787A patent/CL2016000787A1/es unknown
- 2016-04-07 SA SA516370891A patent/SA516370891B1/ar unknown
2018
- 2018-08-30 JP JP2018161767A patent/JP2019011334A/ja active Pending
- 2018-10-03 HR HRP20181582TT patent/HRP20181582T1/hr unknown
- 2018-10-18 CY CY181101050T patent/CY1121105T1/el unknown
2019
- 2019-08-07 US US16/534,263 patent/US20190358240A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP6574415B2 (ja)	2019-09-11
PL3054926T3 (pl)	2018-12-31
RS57882B1 (sr)	2019-01-31
CY1121105T1 (el)	2019-12-11
HRP20221126T1 (hr)	2022-11-25
BR112016007526A8 (pt)	2020-03-03
SI3054926T1 (sl)	2018-10-30
DK3421033T3 (da)	2022-10-10
MY178960A (en)	2020-10-26
EP3054926B1 (en)	2018-07-25
PT3054926T (pt)	2018-10-26
US20190358240A1 (en)	2019-11-28
AU2014332200B2 (en)	2018-10-04
JP2019011334A (ja)	2019-01-24
WO2015054133A1 (en)	2015-04-16
DK3054926T3 (en)	2018-10-29
MX368268B (es)	2019-09-26
SG11201602501VA (en)	2016-04-28
LT3054926T (lt)	2018-11-12
JP2016532649A (ja)	2016-10-20
SA516370891B1 (ar)	2018-08-08
ES2693580T3 (es)	2018-12-12
PT3421033T (pt)	2022-09-23
KR20160060764A (ko)	2016-05-30
SI3421033T1 (sl)	2022-11-30
SMT202200373T1 (it)	2022-11-18
EP3421033B1 (en)	2022-07-27
MX2016004078A (es)	2016-06-06
KR102286386B1 (ko)	2021-08-05
CN106029058A (zh)	2016-10-12
IL244881B (en)	2021-12-01
LT3421033T (lt)	2022-11-10
EA201690594A1 (ru)	2016-09-30
PL3421033T3 (pl)	2022-10-03
AU2014332200A1 (en)	2016-05-19
HUE059757T2 (hu)	2023-01-28
US20160038502A1 (en)	2016-02-11
IL244881A0 (en)	2016-05-31
EA031172B1 (ru)	2018-11-30
HRP20181582T1 (hr)	2018-11-30
EP3421033A1 (en)	2019-01-02
ES2927484T3 (es)	2022-11-07
EP3054926A1 (en)	2016-08-17
CA2926650A1 (en)	2015-04-16
BR112016007526A2 (pt)	2017-08-01
CL2016000787A1 (es)	2016-11-25
PE20160596A1 (es)	2016-06-15
SMT201800507T1 (it)	2018-11-09

Publication	Publication Date	Title
ZA201601344B (en)	2017-05-31	Methods and compositions for rna-guided treatment of hiv infection
HK1223616A1 (zh)	2017-08-04	多環氨基甲酰基吡啶酮化合物和其用於治療感染的用途
HK1223615A1 (zh)	2017-08-04	多環氨基甲酰基吡啶酮化合物和其用於治療感染的用途
HK1221416A1 (zh)	2017-06-02	氧雜雙環庚烷和氧雜雙環庚烯的配製品
HRP20181582T1 (hr)	2018-11-30	Formulacija atazanavira i kobicistata za liječenje hiv-a
HK1223855A1 (zh)	2017-08-11	拉喹莫德和氟吡汀組合物用於治療多發性硬化症
EP2968127A4 (en)	2016-09-07	LOW GLYCEROL PREPARATIONS FOR HIV TREATMENT AND PREVENTION
PL3166642T3 (pl)	2020-11-30	Transdermalne preparaty pergolidu i ich zastosowanie
AU2013101402A4 (en)	2013-12-05	Timber treatment formulations and methods of use